IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers.

Praveen GuruvaiahRomi Gupta

Published in: Journal of translational medicine (2024)

Our study identifies BAY 11-7082 to be an efficacious inhibitor for treating RAS oncogene (HRAS, KRAS, and NRAS) mutant cancer cells. This finding provides new therapeutic opportunity for effective treatment of RAS-mutant cancers.

Keyphrases

wild type
water quality
combination therapy
dna methylation
young adults